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|| Abstract || 
Background: Approximately one-third of people aged 65 years and over who are not living in institutions 
fall at least once a year, with higher rates among those living in institutions. One half of older adults who 
are hospitalized as a result of a fall survive one year later.The importance of fall prevention in older adults 
is well researched, with many established community based programs in the United States focusing on 
exercise and fundamental education for fall reduction. However, new options for prevention are being 
explored. Executive function and gait, both related to falls, may be improved by methylphenidate, 
providing a promising option for fall prevention in older adults. 
Methods: An exhaustive literature search using MEDLINE-PubMed, Web of Science, and Clinical Key was 
conducted. The following search terms were used: “methylphenidate falls prevention,” “methylphenidate 
older adults,” and “falls prevention methylphenidate.” Eligibility criteria were used to screen studies. These 
studies included the use of single dose methylphenidate versus placebo to measure efficacy in falls 
prevention. GRADE was used to assess quality of the resulting studies. 
Results: Two studies were included in this systematic review, meeting the inclusion and exclusion criteria. 
One study was a double-blind RCT in 30 healthy older adults testing improvement of executive, motor and 
balance function. Another study in 26 older adults without dementia but with subjective complaints of 
memory problems tested the modification of markers for fall risk. These studies have medium quality of 
evidence based on GRADE guidelines. 
Conclusion: These studies found that methylphenidate improved gait and executive function in older 
adults, and should be considered by clinicians as a method of fall prevention in this population. These 
results warrant further investigation of methylphenidate use in fall prevention with large-scale studies. 
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|| Abstract  || 
Background: Approximately one-third of people aged 65 years and over who are not living in 
institutions fall at least once a year, with higher rates among those living in institutions. One half 
of older adults who are hospitalized as a result of a fall survive one year later. The importance of 
fall prevention in older adults is well researched, with many established community based pro-
grams in the United States focusing on exercise and fundamental education for fall reduction. 
However, new options for prevention are being explored. Executive function and gait, both relat-
ed to falls, may be improved by methylphenidate, providing a promising option for fall preven-
tion in older adults.  
Methods:  An exhaustive literature search using MEDLINE-PubMed, Web of Science, and Clin-
ical Key was conducted. The following search terms were used: “methylphenidate falls preven-
tion,” “methylphenidate older adults,” and “falls prevention methylphenidate.” Eligibility criteria 
were used to screen studies. These studies included the use of single dose methylphenidate ver-
sus placebo to measure efficacy in falls prevention. GRADE was used to assess quality of the 
resulting studies. 
Results:  Two studies were included in this systematic review, meeting the inclusion and exclu-
sion criteria. One study was a double-blind RCT in 30 healthy older adults testing improvement 
of executive, motor and balance function. Another study in 26 older adults without dementia but 
with subjective complaints of memory problems tested the modification of markers for fall risk. 
These studies have medium quality of evidence based on GRADE guidelines.  
Conclusion: These studies found that methylphenidate improved gait and executive function in 
older adults, and should be considered by clinicians as a method of fall prevention in this popula-
tion. These results warrant further investigation of methylphenidate use in fall prevention with 
large-scale studies.   
Keywords:  Methylphenidate, older adults, and fall prevention 
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Efficacy of Methylphenidate in the Geriatric 
Population for Fall Prevention 
BACKGROUND 
 Approximately one-third of people aged 65 years and over who are not living in 
institutions fall at least once a year, with higher rates among those living in institutions.1 
One half of older adults who are hospitalized as a result of a fall survive 1 year later.2 The 
importance of fall prevention in older adults is well researched, with many established 
community based programs in the United States focusing on exercise and fundamental 
education for fall reduction. While these are key components in fall prevention, there are 
other areas that can be addressed.  According to a study from 2016, direct medical costs 
in 2015 for fatal falls totaled $637.5 million, and $31.3 billion for non-fatal fall related 
injuries among adults over the age of 65. Total cost and fall incidence are found to in-
crease with age.3  
 Methylphenidate (MPH) works as a mild central nervous system (CNS) stimulant. 
It blocks the re-uptake of norepinephrine and dopamine into presynaptic neurons and ap-
pears to stimulate the cerebral cortex and subcortical structures similar to amphetamines.4 
It is postulated that the resulting MPH-induced increases of dopamine and norepinephrine 
could decrease distractibility, improve attention and enhance the saliency of tasks due to 
dopamine’s modulation of motivation, thus improving performance.5 
 Deterioration in balance and gait related to age is a significant contributor to falls 
in older adults.6 Simultaneous performance of a motor or cognitive task is an additional 
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factor that may limit balance control in older adults.6 Executive function (EF) refers to 
higher cognitive processes that use and modify information from posterior cortical senso-
ry systems to modulate behavior, to regulate response inhibition, and to allocate attention 
among tasks that are performed simultaneously.7 Gait utilizes EF, and these age related 
changes in cognition have ramifications for mobility in older adults.8 
 Studies of EF improvement were motivated by an earlier study9 where single dose 
MPH improved gait (e.g. stride time variability), mobility (e.g. Timed Up and Go times), 
and EF (e.g., Go-NoGo accuracy) in relatively healthy older adults. A study conducted by 
Moreau and colleagues10 on patients with advanced Parkinson’s disease who suffered 
from severe gait disorders and freezing of gait, found that MPH improved gait freezing 
and hypokinesia despite the optimal treatment of motor fluctuations with subthalamic 
stimulation and dopaminergic drugs. Decreased EF has been linked to reduced mobility, 
gait instability and the markers of fall risk, but it is unknown if augmenting EF will affect 
fall risk or gait.8  
 While MPH is indicated and a proven treatment option in the geriatric population 
for ADHD, narcolepsy, and major depressive disorder, there are no indications for fall 
prevention.4 It shows promise, so can single dose methylphenidate be used safely and ef-
fectively as a method of fall prevention in older adults?  
METHODS 
 An exhaustive literature search using MEDLINE-PubMed, Web of Science, and 
Clinical Key was conducted. The following search terms were used: “ methylphenidate 
falls prevention,” “methylphenidate older adults” and “falls prevention methylphenidate.” 
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Sources used in these studies were examined for accuracy and used if relevant. Inclusion 
and exclusion criteria were applied to analyze each study. Studies evaluating the use of 
single dose methylphenidate versus placebo to measure efficacy in fall prevention were 
included. Studies were excluded if they were not a double-blinded RCT. Grading of Rec-
ommendations Assessment, Development and Evaluation (GRADE) Working Group 
guidelines was used to assess quality of the resulting studies.11 
RESULTS 
 Initial searches resulted in 146 studies for review. After reading titles and ab-
stracts, 2 studies8,17 were selected that met eligibility criteria. Both of these studies are 
RCTs in the older adult population, measuring single dose MPH vs. placebo, and 1 is a 
cross-over study.8 (See Table 1.)  
Ben-Itzhak et al 
 This study8 was a double blinded, randomized, placebo-controlled, cross-over 
study using single-dose MPH vs. placebo. The authors wanted to look at whether or not 
MPH modifies risk markers of fall risk in older adults. The study took place in an outpa-
tient movement disorders clinic and included 26 older adults, mean age of 73.8 years, 
with subjective complaints of “memory problems” but who were non-demented. Using 
the Mini Mental State Examination (MMSE), DSM IV and ICD-10 criteria, people with 
dementia were excluded from the study. Due to MPH’s side effect profile, subjects were 
excluded if they had uncontrolled high BP, heart failure or cardiac arrhythmia, cardiovas-
cular or respiratory diseases, history of epilepsy, glaucoma, major depression, Parkinson’s 
disease, or other neurodegenerative diseases.8   
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 During the first visit, medical and fall history were reviewed to characterize the 
study population in combination with certain tests that were administered. The Geriatric 
Depression Scale (GDS) to evaluate emotional well being and depressive symptoms, the 
clock drawing test to measure cognitive function, the Charlson Comorbidity Index to 
quantify disease burden, the Barthel Activities of Daily Living Index and the French Ac-
tivities Index to characterize disability and lifestyle and functional independence, and the 
Activities-specific Balance Confidence Scale to assess fear of falling. As part of the cog-
nitive assessment, the MMSE was used to screen for dementia.8   
 The course of the study was 2 weeks, with the initial visit for baseline, then 2 
more evaluations each 2 hours after subjects took 20mg MPH (Ritalin®) or placebo. The 
Timed Up and Go (TUG) test was used to assess fall risk and functional mobility, with 
the second of 2 trials being used as per standard procedures to minimize practice effects. 
Stride time variability, which quantifies automaticity of gait, was evaluated by having the 
subjects walk their normal pace on level ground for 2 minutes while wearing pressure-
sensitive insoles.8 Dual-task methods that were previously established12-13 were used to 
measure gait speed, stride time and variably to stride time using the coefficient of varia-
tion (CV). A high CV value signifies reduced rhythmicity and automaticity, which are 
associated with elevated fall risk.12-13  
 The Go-NoGo test was used to measure EF, a well-established cognitive test that 
measures the means with which an individual is able to continue with an activity in the 
face of competing stimuli and to inhibit a response.14 Reaction time in the Go-NoGo was 
measured to evaluate stimulant effects, and the accuracy of each test was evaluated to 
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quantify EF.8 In order to evaluate possibility of observed motor effects being specific to 
gait, catching and finger tapping abilities were measured. In this computerized game,15 
participants catch an object falling vertically from the top of the computer screen, testing 
hand-eye coordination and scanning. Outcome measures of this test have been associated 
with higher-level cognitive function and EF.16  
 Statistical analysis revealed that TUG times decreased compared to baseline (P = 
0.004) and compared to the effect seen with placebo (P = 0.03) on 20mg MPH. Stride 
time variability was significantly improved on MPH compared to baseline (P = 0.28), but 
not compared to placebo (P = 0.551). MPH was also shown to significantly improve Go-
NoGo accuracy from baseline (P = 0.030), and above the placebo effect (P = 0.027). 
MPH also improved catch game accuracy (P = 0.044) and catch game time to first move 
(P = 0.034), while the placebo did not. Similar effects on Go-NoGO reaction time were 
recorded in both MPH and placebo groups.8 (See Table 2)  
 Limitations of this study include the size of the study population, which only had 
26 subjects. The number of subjects, in addition to subject characteristics, raises ques-
tions regarding the generalizability of the findings. The length of the study was only 2 
weeks, which may also limit its application. Chronic administration of MPH was not 
evaluated in lowering fall rates, whether the administered dose is optimal, or whether the 
potential benefits outweigh the possible risks. Adverse events were not observed in this 
study, but safe administration of MPH in older adults needs to be further investigated.8  
Shorer et al 
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 This was the most recent study,17 a double-blinded, RCT using single dose MPH 
(Group X) vs. placebo. This study was motivated by the evidence for benefits of MPH for 
divided attention and on the fact that MPH may improve EF, which generally declines 
with aging.18 The authors wanted to test the hypothesis that administering a single dose of 
MPH will improve gait and postural stability of older adults in both single-task (ST) and 
dual-task (DT) conditions. This study was conducted at the University of Negev, Beer-
Sheeva, Israel, and included 30 healthy older adults with a mean age of 74.9 years. Ex-
clusion criteria included inability to walk independently at least 20 meters, serious visual 
impairment, severe peripheral or compression neuropathies, symptomatic cardiovascular, 
musckuloskeletal or neurologic disorders that may interfere with gait, being under the 
active treatment of cancer and a score lower than 24 on MMSE.17  
 After completion of the baseline visit, subjects were given either 10mg MPH or 
placebo in a randomized, double blinded fashion and given a 1.5 hour break to allow 
peak plasma concentration. The postural stability protocol started by having participants 
stand upright on a force platform, a Kistler 9287 single force platform, which measures 
the time-varying displacement of the center of pressure (CoP) under a participant’s feet. 
Fourteeen 30-second trails were conducted for 2 task conditions. Two task conditions in-
cluded 7 ST trails, which had participants stand upright with eyes closed and blindfolded, 
and 7 DT trials, where participants were similarly standing upright and blindfolded but 
also required to perform a memory attention-demanding task. These attention-demanding 
tasks during DT trials included listening to a collection of 15 words, one word every 2 
seconds, with the instruction of counting the number of words that did not start with a 
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certain letter while standing still. After completion of a trial, they would recall the num-
ber of words they counted that did not start with that particular letter.  Participants were 
allowed to practice the trials beforehand, and were not given specific attention focus in-
structions.17 
 Force platform data were sampled at 100 Hz frequency and analyzed using auto-
matic code written in Metlab (Math Works Inc, Cambridge, MA), to obtain 4 well estab-
lished parameters of postural stability. These parameters included mediolateral (ML) CoP 
range, anterioposterior (AP) CoP range, mean velocity of CoP sway, and sway area-ellip-
tical area of the CoP points. Each participant’s trials were computed and averaged for 
each set of 7 trials to get an average value for each parameter in each experimental condi-
tion for each participant.17  
 After a 10-minute break, the narrow base walk test (NBWT)19 was modified for 
clinical use and used to measure gait under ST and DT conditions, which required partic-
ipants to walk down a 6m narrow path for 6 trials. There were 3 different types of cogni-
tive tasks, saying the day of the week backwards in the first trail, the months of the year 
backwards in the second trial, and to count down in increments of 5 from 100 to 50 in the 
third trial. Video of trials was later analyzed for trial times, detected steps errors, calculat-
ed step error rate, number of steps, and calculated trail velocity. All NBWT parameters of 
participant’s trials were averaged for each set of 3 trials to obtain average values of each 
participant in ST and DT conditions.17  
 Statistical analysis found a significant Group X Time interrogation in AP sway 
rang in DT condition (F = 1.7, P = .05), indicating significantly improved stability in the 
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experimental group with small effect size during DT and not during ST. There was also a 
significant main effect for time in ML sway range, mean velocity, and sway area during 
DT condition (F = 6.4, P = .016; F = 19.6, P = .001; and F = 10.6, P = .003, respectively) 
and in mean velocity and sway area during ST condition (F = 4.5, P = .04 and F = 4.0, P = 
.05, respectively), driven by improvement over time in both study groups. A 57% reduc-
tion in the number of step errors in the experimental group, and no equivalent improve-
ment in place controls was reported. In the experimental group’s number of step errors, a 
significant Group X Time interaction was found in the ST condition (F = 4.5, P = .04). In 
the DT condition, significant Group X Time interaction effect was found for trial velocity, 
number of step errors, and trial time after taking MPH (F = 5.2, P = .04; F = 5.7, P = .02; 
and F = 6.1, P = .02, respectively). In addition, the study revealed a significant Group X 
Time interaction effect for all 3 variables representing motor performance in the third tri-
al; trial velocity, trial time, and number of steps improved in the experimental group only 
(F = 7.4, P  = .009; F = 6.7, P = .01; and F = 9.7, P = .004, respectively), which shows 
that in the trials with MPH treatment, a learning effect occurred. No significant interac-
tion effect between group and time or significant main effect for time was observed for 
the cognitive task error rate during postural stability and NBWT in ST or DT conditions.
17  (See Tables 3 & 4)  
 Limitations of this study include the sample size, which is only 30 older adults 
pooled from a defined relatively healthy community-based population. The study has 
strict health inclusion criteria, which excludes application of results to extremely weak or 
institutionalized older adults. A confounder was introduced into the design of the experi-
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ment from the easier work monitoring cognitive task during the standing trials and the 
fluency tasks during the gait trials. Also, one cannot make strong conclusions about the 
relative efficacy of drug treatment effects for DT balance versus walking, due to passive 
word monitoring not requiring EFs as much as fluency.17  
DISCUSSION 
 Rates of falling among older adults continue to rise despite prevention efforts in 
the US. The components of preventing falls in these programs are primarily awareness, 
physical strengthening and maintaining activity levels. Though these intervention pro-
grams are effective, alternative options can be explored. The focus of this systematic re-
view was to determine efficacy of MPH as a reliable means to prevent falls in older 
adults.  
 The results of the reviewed studies8,17 both show a positive correlation between 
low, single-dose MPH and improvement in gait and EF. Though the use of this medica-
tion for fall prevention is not established, these studies provide evidence of improvement 
in key components of falls that can make a difference in preventing falls in older adults. 
Providers may want to consider the use of MPH in fall prevention, particularly in patients 
who may not adhere to other manners of prevention.  
 These 2 studies were assessed using GRADE criteria, and both only scored with 
low quality (Table 1). Additional limitations in one study8 includes: subjects were healthy 
relative to their age with strict inclusion criteria, and needed to ambulate without as-
sistance to be a study participant. This may limit application to groups outside of this cat-
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egory of older adults. Though dementia was ruled out with MMSE, participants also had 
subjective complaints of “memory problems” which is broad and not specific. Another 
study17 did not provide the method of recruitment, which could indicate selection bias, 
and did not measure adverse side effects during the study. Also, this study’s trials took 
place in a single day, limiting long term application.  Both studies had a small sample 
size, which does not ensure that the results can be generalized to a larger population. De-
spite the limitations of these studies, they both provide a basis for further studies. 
 The premise of prevention would mean long term treatment with MPH, and this 
means that larger studies, with more variance in participants are needed. One reason for 
strict inclusion and exclusion criteria in these studies is due to known side effects of 
MPH. Increasing heart rate and blood pressure in older adults is far from ideal. However, 
no adverse events were recorded during the first study,8 with no increases in systolic 
blood pressure, diastolic blood pressure, or heart rate. Though this study only took place 
over 2 weeks, so this warrants a longer study with MPH. 
 With MPH being used in the geriatric population for narcolepsy, ADHD and 
MDD, even with the side effects taken into consideration, then perhaps it should be con-
sidered as a viable option in fall prevention treatment. By improving gait and executive 
function, prevention of falls with methylphenidate could reduce the number of hospital-
izations, burden to health care systems such as the annual $32 billion in direct medical 
costs and prevent morbidity related to falls in this population.  
CONCLUSION 
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 MPH was able to improve gait function in healthy older adults, especially in com-
plex tasks that require higher executive control. Measures of gait and EF showed im-
provement in groups taking MPH compared to placebo in both studies. There are a num-
ber of limitations in these studies, but the results provide a foundation for a large scale 
study to solidify MPH’s use as a fall prevention medication in older adults. The cost of 
falls to the medical system, and potential for improvement in quality of life for older 
adults warrants a larger scale study.  
 Clinicians should continue with traditional fall prevention methods that focus on 
exercise and balance, and consider the future use of MPH as an alternative treatment once 
large scale studies have been conducted that demonstrate efficacy and with more general-
ized applications to older adults.There is promise in this drug’s ability to aid in improve-
ment in the quality of life for the geriatric population. 
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Table 1: Quality Assessment of Reviewed Articles
Outcome
Numbe
r of 
studies
Study 
Desig
ns
Downgrade Criteria Upgra
de 
Criteri
a
Qua
lityLimita
tions
Indirec
tness
Inconsis
tency
Imprec
ision
Publica
tion 
bias
Gait 
Improvement
2 RCTs Serious 
(1,2)
Serious 
(3)
Not 
Serious
Not 
Serious
Unlikely None Low
Executive 
Function 
improvement
2 RCTs Serious 
(1,2)
Serious 
(3)
Not 
Serious
Not 
Serious
Unlikely None Low
1: Both studies have small sample sizes, and were conducted over short periods of time. 
These studies were not long enough to measure adverse side effects from long term use. 
2: One study does not list recruiting methods, which could mean selection bias. 
3: Studies used surrogate outcomes
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Table 2: Ben-Itzak et al8  P-values
Baseline/
Unmedicat
ed
MPH Placebo Baselines 
vs. MPH
Baseline 
vs. 
Placebo
MPH vs. 
Placebo
Gait speed 
(m/sec)
1.12 ± 0.6 1.20 ± 0.05 1.19 ± 0.05 0.001 0.003 0.354
Stride 
Time (sec)
1.09 ± 0.02 1.06 ± 0.02 1.07 ± 0.02 0.025 0.006 0.517
Stride 
Time 
Variability 
(%)
3.52 ± 0.44 2.72 ± 0.24 3.08 ± 0.32 0.028 0.395 0.551
Timed Up 
& Go (sec)
10.3 ± 0.6 9.4 ± 0.5 9.9 ± 0.6 0.004 0.206 0.03
*Entries are mean±SE. P-values  
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Table 3: Shorer et al17

Eﬀect of Single Dose Methylphenidate (MPH) on Postural Stability Parameters Under Single- and Dual-Task 
Conditions (i.e., eyes closed narrow base stance)
Postural Stability 
Variables
Group Baseline Post-
Test
ANOVA 
(baseline to 
post-test) T
ANOVA 
(baseline to 
post-test) T X G
Single Task 
AP sway range 
(mm)
Exeriment
al

Control
34.5 ± 7.8

31.7 ± 8.2
34.7 ± 7.5

30.8 ± 5.7
F = 0.29; p = 0.6 F = 0.45; p = 0.51
ML sway range 
(mm)
Experimen
tal 

Control
41.1 ± 7.2

35.8 ± 8.5
39.3 ± 7.1

34.3 ± 8.5
F = 3.9; p = .057 F = 0.02; p = 0.89
Mean velocity 
(mm2/s)
Experimen
tal 

Control
34.7 ± 
11.4

33.1 ± 
11.5
32.9 ± 9.7

31 ± 8.5
F = 4.5; p = 0.04 F = 0.5; p = 0.8
Sway area (mm2) Experimen
tal

Control
132.3 ± 
51.8

118.7 ± 
58.7
123.7 ± 
41

107.7 ± 
40.7
F = 4.0; p = 0.05 F = 0.06; p = 0.81
Cognitive task 
errors
Experimen
tal

Control
0

0
0

0
NA NA
Dual Task 
AP sway range 
(mm)
Experimen
tal

Control
42.6 ± 9.6

35.5 ± 6.6
41.9 ± 9.3

37.1 ± 6.5
F = 0.28; p = 0.6 F = 1.7; p = 0.05
ML sway range 
(mm)
Experimen
tal

Control
51.4 ± 9.4

42.3 ± 8.9
48.1 ± 8.2

40.4 ± 9.2
F = 6.3; p=0.016 F = 0.46; p = 0.5
Mean velocity 
(mm2/s)
Experimen
tal

Control
39.6 ± 
11.7

34.7 ± 
10.4
36.2 ± 9.9

31.9 ± 8.8
F = 19.6; p = 
0.001
F = 0.19; p = 0.7
Sway area (mm2) Experimen
tal

Control
183 ± 64.7

141.1 ± 
49.8
163.7 ± 
53.4

133 ± 
51.2
F = 10.6; p = 
0.003

F = 1.8; p = 0.19
Cognitive task 
errors
Experimen
tal

Control
5.2 ± 4.7

3.2 ± 2.3
2.8 ± 3.1

3.0 ± 1.6
F = 2.8; p = 0.1 F = 2.0; p = 0.17
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Note: AP = anterioposterior; ANOVA = analysis of variance; G = group; NA = not applicable; 
ML = mediolateral; T = time.

Values are M ± 1 SD. Comparison of baseline and postintervention between the two groups 
based on repeated measures ANOVA (T x G).
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Table 4: Shorer et al17

Eﬀect of Single Dose Methylphenidate (MPH) on 6-m Narrow Base Walking Parameters Under Single-Task Condition 
(panel A) and Dual-Task Conditions (panel B)
Gait Variable Group Baseline Post-
Test
ANOVA 
(baseline 
to post-
test) T
ANOVA 
(baseline 
to post-
test) T X 
G
ANOVA 
(baseline 
to post-
test) T X Tr
Panel A; Single 
task 
Trial velocity (m/s)
Exeriment
al

Control
0.82 ± 0.3

0.77 ± 0.2
0.88 ± 0.3

0.83 ± 
0.25
F = 2.7;        
p = 0.1
F = 0.002;    
p = 0.97
F = 1.1;            
p = 0.2
Trial time (s) Experime
ntal 

Control
8.4 ± 3.4

8.6 ± 3.1
6.9 ± 2.2

7.8 ± 2.5
F = 8.3; 

p = .007
F = 1.0; 

p = 0.3
F = 0.9; 

p = 0.4
Number of step 
errors
Experime
ntal 

Control
1.6 ± 1.2

2.0 ± 3.3
0.7 ± 0.8

1.9 ± 2.7
F = 3.7; 

p = 0.06
F = 4.5;  
p = 0.04
F = 1.7; 

p = 0.2
Cognitive task 
errors rate (%)
Experime
ntal

Control
0.6 ± 2.4

0.04 ± 0.01
0.05 ± 
0.01

0 ± 0 
F = 0.49; 

p = 0.48
F = 0.896; 

p = 0.37
F = 3.5; 

p = 0.04
Panel B: Dual task 
(average value) 
Trial velocity (m/s)
Experime
ntal

Control
0.61 ± 0.3

0.56 ± 0.2
0.71 ±0.3

0.59 
±0.25
F = 8; 

p = 0.008
F = 5.2;  
p = 0.04 
F = 2.3; 

p = 0.05
Trial time (s) Experime
ntal

Control
12.7 ± 7

12.0 ± 4.5
10.1 ± 4.9

12.0 ± 5.2
F = 4.1; 

p = 0.05
F = 6.1;  
p = 0.02 
F = 0.16;

 p = 0.85
Number of step 
errors
Experime
ntal

Control
2.2 ± 1.9

2.6 ± 1.4
0.98 ± 1.1

2.3 ± 3.1
F = 1.1; 

p = 0.03 
F =5.7;  
p = 0.02
F = 3.3; 

p = 0.04
Cognitive task 
errors rate (%)
Experime
ntal

Control
0.02 ± 0.03

0.06 ± 0.16
0.01 ± 
0.015

0.003 ± 
0.007
F = 0.6 ; 

p = 0.4
F = 1.7; 

p = 0.21
F = 4.2; 

p = 0.03 
Note: ANOVA = analysis of variance; G = group; T = time; Tr = trial number.

The average of all three trials is presented. Values are M ± 1 SD (95% confidence interval for 
means). Comparison of baseline and post-intervention between the two groups based on 
repeated measures ANOVA (Test x Group x Trial condition).
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